Non–Cystic Fibrosis Bronchiectasis: Long-term, Low-dose Erythromycin Is Preferred
April 1st 2013Take-home advice for primary physicians . . . restrict long-term maintenance erythromycin therapy to subsets of patients to protect against increases in macrolide-resistant bacteria in the broader community. Details here . . .